What is InMed Pharmaceuticals' stock price target for 2024?

0 Wall Street analysts have issued 12 month price targets for InMed Pharmaceuticals' stock. Their INM share price targets range from $45.00 to $45.00. On average, they expect the company's stock price to reach $45.00 in the next year. This suggests a possible upside of 9,900.0% from the stock's current price. View analysts price targets for INM or view top-rated stocks among Wall Street analysts .

How have INM shares performed in 2023?

InMed Pharmaceuticals' stock was trading at $2.02 on January 1st, 2023. Since then, INM stock has decreased by 77.7% and is now trading at $0.45. View the best growth stocks for 2023 here .

Are investors shorting InMed Pharmaceuticals?

InMed Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 4,900 shares, a decrease of 74.1% from the October 31st total of 18,900 shares. Based on an average daily volume of 1,740,000 shares, the short-interest ratio is currently 0.0 days. View InMed Pharmaceuticals' Short Interest .

When is InMed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 16th 2024. View our INM earnings forecast .

How were InMed Pharmaceuticals' earnings last quarter?

InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($6.25) EPS for the quarter, topping analysts' consensus estimates of ($8.75) by $2.50. InMed Pharmaceuticals had a negative trailing twelve-month return on equity of 57.65% and a negative net margin of 147.87%.

When did InMed Pharmaceuticals' stock split?

Shares of InMed Pharmaceuticals reverse split on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of InMed Pharmaceuticals?

Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

InMed Pharmaceuticals Stock Price, News & Analysis (NASDAQ:INM)

$0.45

+0.01 (+2.27%)

(As of 12/1/2023 ET)

Compare

Today's Range: $0.41
▼
$0.45
50-Day Range: $0.37
▼
$0.99
52-Week Range: $0.29
▼
$3.03

Volume: 178,540 shs
Average Volume: 263,972 shs
Market Capitalization: $2.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $45.00

InMed Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: 0.00 Rating Score
Upside/Downside: 9,900.0% Upside
$45.00 Price Target
Short Interest: Healthy
0.09% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.43
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $45.00, InMed Pharmaceuticals has a forecasted upside of 9,900.0% from its current price of $0.45.
Amount of Analyst Coverage
InMed Pharmaceuticals has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.09% of the outstanding shares of InMed Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
InMed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in InMed Pharmaceuticals has recently decreased by 74.07%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
InMed Pharmaceuticals does not currently pay a dividend.
Dividend Growth
InMed Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INM.

3.0

News and Social Media Coverage

News Sentiment
InMed Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for InMed Pharmaceuticals this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added InMed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.39% of the stock of InMed Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 0.47% of the stock of InMed Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Price to Book Value per Share Ratio
InMed Pharmaceuticals has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About InMed Pharmaceuticals Stock (NASDAQ:INM)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

INM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INM Stock News Headlines

November 14, 2023 | finance.yahoo.com

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

November 8, 2023 | msn.com

InMed Pharmaceuticals files to sell 12.57M shares for holders

December 3, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 8, 2023 | morningstar.com

InMed Pharmaceuticals Inc INM

November 2, 2023 | finance.yahoo.com

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

October 27, 2023 | finance.yahoo.com

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

October 25, 2023 | investorplace.com

Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today?

October 24, 2023 | msn.com

InMed Pharmaceuticals to raise $5.2M via private placement

December 3, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

October 24, 2023 | finance.yahoo.com

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

October 24, 2023 | benzinga.com

Dow Surges 250 Points; US Manufacturing PMI Tops Expectations

October 24, 2023 | benzinga.com

Why InMed Pharmaceuticals Stock Is Soaring Tuesday

October 3, 2023 | theglobeandmail.com

InMed Pharmaceuticals (NASDAQ: INM) Releases FY 2023 Report, Shares Corporate Update

September 29, 2023 | finance.yahoo.com

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

September 15, 2023 | benzinga.com

This Clinical Stage BioPharma Is Seeing Solid Growth In Rare Cannabinoid Demand From The Health And Wellness Sector

September 7, 2023 | finance.yahoo.com

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

July 22, 2023 | au.finance.yahoo.com

INM - InMed Pharmaceuticals Inc.

July 21, 2023 | finance.yahoo.com

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

June 22, 2023 | msn.com

Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

June 22, 2023 | finance.yahoo.com

Why Are InMed Pharmaceuticals Stock Trading Lower Today

June 22, 2023 | finance.yahoo.com

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

June 1, 2023 | msn.com

Study Unveils Rare Cannabinoid As Promising Hope For Alzheimer's, Parkinson's & Huntington's Treatment

June 1, 2023 | finanznachrichten.de

InMed Pharmaceuticals: InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

June 1, 2023 | finance.yahoo.com

InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

May 24, 2023 | finance.yahoo.com

InMed to Participate in Upcoming Virtual Investor Events

May 18, 2023 | finance.yahoo.com

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

May 15, 2023 | seekingalpha.com

InMed Pharmaceuticals GAAP EPS of -$0.60, revenue of $1.03M

See More Headlines

Receive INM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 12/03/2023
Next Earnings (Estimated): 2/16/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INM
CUSIP: N/A
CIK: 1728328
Web: www.inmedpharma.com
Phone: 604-669-7207
Fax: N/A
Employees: 13
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $45.00
High Stock Price Target: $45.00
Low Stock Price Target: $45.00
Potential Upside/Downside: +9,900.0%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,950,000.00
Net Margins: -147.87%
Pretax Margin: -147.74%
Return on Equity: -57.65%
Return on Assets: -49.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.19
Quick Ratio: 5.35

Sales & Book Value

Annual Sales: $4.14 million
Price / Sales: 0.57
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.82 per share
Price / Book: 0.25

Miscellaneous

Outstanding Shares: 5,260,000
Free Float: 5,182,000
Market Cap: $2.37 million
Optionable: Not Optionable
Beta: -0.04

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Eric A. Adams B.S. Chem. (Age 59)
M.I.B., President, CEO & Director
Comp: $347.82k
Mr. Michael Woudenberg P.Eng. (Age 54)
Chief Operating Officer
Comp: $287.54k
Ms. Alexandra Diane-Janet Mancini M.Sc. (Age 70)
Senior Vice President of Clinical & Regulatory Affairs
Comp: $279.39k
Dr. Sazzad Hossain M.Sc. (Age 65)
Ph.D., Co-Founder
Comp: $133.8k
Mr. Jonathan R. Tegge (Age 33)
Interim Chief Financial Officer
Ms. Sarah Li CPA
CGA, VP of Accounting & Controller
Colin Clancy
Senior Director of Investor Relations
Mr. Jerry P. Griffin
Vice President of Sales & Marketing
Dr. Eric Chih-Hsien Hsu (Age 53)
Senior Vice President of Preclinical Research & Development
Comp: $253.46k
Dr. Shane A. Johnson Ph.D.
Senior VP & GM of BayMedica

Key Competitors

View All Competitors

INM Stock Analysis - Frequently Asked Questions

What is InMed Pharmaceuticals' stock price target for 2024?: 0 Wall Street analysts have issued 12 month price targets for InMed Pharmaceuticals' stock. Their INM share price targets range from $45.00 to $45.00. On average, they expect the company's stock price to reach $45.00 in the next year. This suggests a possible upside of 9,900.0% from the stock's current price.
View analysts price targets for INM or view top-rated stocks among Wall Street analysts.
How have INM shares performed in 2023?: InMed Pharmaceuticals' stock was trading at $2.02 on January 1st, 2023. Since then, INM stock has decreased by 77.7% and is now trading at $0.45.
View the best growth stocks for 2023 here.
Are investors shorting InMed Pharmaceuticals?: InMed Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 4,900 shares, a decrease of 74.1% from the October 31st total of 18,900 shares. Based on an average daily volume of 1,740,000 shares, the short-interest ratio is currently 0.0 days.
View InMed Pharmaceuticals' Short Interest.
When is InMed Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, February 16th 2024.
View our INM earnings forecast.

How were InMed Pharmaceuticals' earnings last quarter?: InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($6.25) EPS for the quarter, topping analysts' consensus estimates of ($8.75) by $2.50. InMed Pharmaceuticals had a negative trailing twelve-month return on equity of 57.65% and a negative net margin of 147.87%.
When did InMed Pharmaceuticals' stock split?: Shares of InMed Pharmaceuticals reverse split on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
How do I buy shares of InMed Pharmaceuticals?: Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:INM) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial